



Aratana Makes Post-Op Pain Therapeutic Commercially Available

On October 5, Aratana made NOCITA® (bupivacaine liposome injectable suspension) commercially available to veterinarians in the United States – the Company's first commercial launch of an FDA-approved therapeutic. The U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved Nocita as a local post-operative analgesia for cranial cruciate ligament surgery in dogs on August 12, 2016.

Nocita is a long-acting, local anesthetic that lasts up to 72 hours post-surgery by releasing bupivacaine over time from multi-vesicular liposomes deposited in the tissue. The therapeutic is administered as a single dose by tissue infiltration during closure of cranial cruciate ligament surgery in dogs.

"As we pivot to a fully integrated company, we believe Aratana will continue to grow the already thriving Animal Health Corridor ecosystem and validate that the region can be a leading innovation hub for biotech," explained Dr. Steven St. Peter, Chief Executive Officer and President of Aratana.

Aratana anticipates making ENTYCE® (capromorelin oral solution), indicated for appetite stimulation, available to veterinarians in the first quarter of 2017 in conjunction with North American Veterinary Conference (NAVC).

Important Safety Information

NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full [Prescribing Information](#) for more detail.

ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full [Prescribing Information](#) for more detail.